| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1613-mCRC, Adv/Met, TP vs CETIRI | 1 | N | 0 Screening | 130 | 240 | 0 | 0 | 0 | 0 | 0 | 11/27/2017 | ||
| 240 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | N | 1 Trastuzumab + Pertuzumab | 26 | 0 | 0 | 0 | 0 | 0 | 11/27/2017 | |||||
| 2 Cetuximab + Irinotecan | 28 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 54 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 3 | Y | 3 Crossover: Trastuz + Pertuz | 20 | 1 | 0 | 0 | 0 | 0 | 11/27/2017 | |||||
| 20 | 1 | 0 | 0 | 0 | 0 | |||||||||
| S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | 1 | Y | 1 Ramucirumab + Paclitaxel | 94 | 15 | 3 | 0 | 0 | 0 | 0 | 06/01/2020 | 156 | 56 | |
| 2 FOLFIRI | 12 | 3 | 1 | 1 | 0 | 0 | ||||||||
| 27 | 6 | 1 | 1 | 0 | 0 | |||||||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | 1 | Y | 1 Olaparib + Pembrolizumab | 88 | 18 | 11 | 7 | 3 | 1 | 0 | 02/22/2021 | 219 | 79 | |
| 2 Olaparib | 15 | 7 | 5 | 2 | 0 | 0 | ||||||||
| 33 | 18 | 12 | 5 | 1 | 0 | |||||||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | 1 | Y | 1 Capecitabine Temozolomide | 154 | 11 | 11 | 7 | 5 | 2 | 0 | 05/05/2022 | 162 | 55 | |
| 2 Observation | 7 | 6 | 1 | 0 | 0 | 0 | ||||||||
| 18 | 17 | 8 | 5 | 2 | 0 | |||||||||
| S2107-Colorectal, BRAF mut, Enc + CET +/-Nivo | 1 | Y | 1 Nivolumab + Encorafenib + Cetuximab | 84 | 15 | 15 | 12 | 6 | 3 | 0 | 07/19/2022 | 179 | 65 | |
| 2 Encorafenib Cetuximab | 11 | 11 | 8 | 4 | 0 | 0 | ||||||||
| 26 | 26 | 20 | 10 | 3 | 0 | |||||||||
| Yes | A021806-Pancreas, Perioperative vs Adjuvant Chemo | 0 | E | Total Registrations | 25 | 8 | 4 | 2 | 0 | 0 | 10/08/2020 | 272 | 124 | |
| 25 | 8 | 4 | 2 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 20 | 5 | 2 | 2 | 0 | 0 | 10/08/2020 | |||||
| 20 | 5 | 2 | 2 | 0 | 0 | |||||||||
| A022104-Rectal, Loc Adv, Triplet vs Doublet Chemo | 1 | E | Total Registrations | 3 | 3 | 3 | 3 | 1 | 0 | 03/13/2023 | 43 | 29 | ||
| 3 | 3 | 3 | 3 | 1 | 0 | |||||||||
| EA2174-Esoph, Peri-Op Nivolumab +/- Ipilimumab | 1 | E | Total Registrations | 6 | 4 | 1 | 0 | 0 | 0 | 06/01/2021 | 218 | 96 | ||
| 6 | 4 | 1 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 3 | 2 | 2 | 0 | 0 | 0 | 06/01/2021 | |||||
| 3 | 2 | 2 | 0 | 0 | 0 | |||||||||
| EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI | 1 | E | Total Registrations | 23 | 8 | 4 | 3 | 3 | 1 | 11/18/2020 | 304 | 113 | ||
| 23 | 8 | 4 | 3 | 3 | 1 | |||||||||
| EA2192-Panc, APOLLO | 0 | E | Total Registrations | 2 | 2 | 2 | 1 | 1 | 0 | 12/07/2022 | 136 | 69 | ||
| 2 | 2 | 2 | 1 | 1 | 0 | |||||||||
| NRGGI008-Colon, Stg III, Adj Chemo | 1 | E | Total Registrations | 9 | 9 | 9 | 3 | 1 | 0 | 12/08/2022 | 164 | 45 | ||
| 9 | 9 | 9 | 3 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 5 | 5 | 5 | 3 | 2 | 1 | 12/08/2022 | |||||
| 5 | 5 | 5 | 3 | 2 | 1 | |||||||||
| No | A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo | 1 | E | Total Registrations | 23 | 6 | 4 | 3 | 1 | 0 | 06/11/2019 | 216 | 93 | |
| 23 | 6 | 4 | 3 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 06/11/2019 | |||||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| A022102-Gastric, FOLFIRINOX +/-Nivo vs FOLFOX +/ Nivo | 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 05/15/2023 | 2 | 2 | ||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| EA2176-Anal, Met, Immune Check Pt Inhibition + Chemo | 1 | E | Total Registrations | 18 | 6 | 4 | 2 | 1 | 0 | 08/09/2021 | 193 | 86 | ||
| 18 | 6 | 4 | 2 | 1 | 0 | |||||||||
| EA2182-Anal, Erly, DECREASE | 0 | E | Total Registrations | 7 | 6 | 3 | 2 | 1 | 0 | 05/04/2022 | 271 | 91 | ||
| 7 | 6 | 3 | 2 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 8 | 7 | 4 | 3 | 1 | 0 | 05/04/2022 | |||||
| 8 | 7 | 4 | 3 | 1 | 0 | |||||||||
| EA2187-ICC, Carboplatin+Paclitaxel +/- Pevonedistat | 1 | E | Total Registrations | 7 | 0 | 0 | 0 | 0 | 0 | 12/09/2020 | 227 | 69 | ||
| 7 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA2197-Gal, Rando Perioperative TX | 1 | E | Total Registrations | 3 | 2 | 1 | 1 | 1 | 0 | 11/18/2021 | 146 | 77 | ||
| 3 | 2 | 1 | 1 | 1 | 0 | |||||||||
| NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy | 1 | Y | Total Registrations | 15 | 0 | 0 | 0 | 0 | 0 | 04/18/2018 | 341 | 118 | ||
| 15 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGGI005-COLON,Stg IIA, ctDNA in Adjuvant Chemotherapy | 1 | Y | Total Registrations | 35 | 20 | 7 | 3 | 2 | 1 | 07/06/2020 | 424 | 158 | ||
| 35 | 20 | 7 | 3 | 2 | 1 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| EA2192 Panc, APOLLO | 1 Randomization | 29-Apr-21 | 136 | 69 |
| NRGGI008 Colon, Stg III, Adj Chemo | 3 Randomization | 10-Mar-22 | 164 | 45 |